SwePub
Sök i SwePub databas

  form:Ext_t

Träfflista för sökning "WFRF:(Bengtsson M) "

form:Search_simp_t: WFRF:(Bengtsson M)

  • navigation:Result_t 1-10 navigation:of_t 636
hitlist:Modify_result_t
   
hitlist:Enumeration_thitlist:Reference_thitlist:Reference_picture_thitlist:Find_Mark_t
1.
  •  
2.
  • 2019
  • swepub:Mat_article_t (swepub:level_refereed_t)
  •  
3.
  •  
4.
  • Abe, O, et al. (creator_code:aut_t)
  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  • 2005
  • record:In_t: The Lancet. - 1474-547X. ; 365:9472, s. 1687-1717
  • swepub:Mat_article_t (swepub:level_refereed_t)abstract
    • Background Quinquennial overviews (1985-2000) of the randomised trials in early breast cancer have assessed the 5-year and 10-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival. Here, we report the 10-year and 15-year effects. Methods Collaborative meta-analyses were undertaken of 194 unconfounded randomised trials of adjuvant chemotherapy or hormonal therapy that began by 1995. Many trials involved CMF (cyclophosphamide, methotrexate, fluorouracil), anthracycline-based combinations such as FAC (fluorouracil, doxombicin, cyclophosphamide) or FEC (fluorouracil, epirubicin, cyclophosphamide), tamoxifen, or ovarian suppression: none involved taxanes, trastuzumab, raloxifene, or modem aromatase inhibitors. Findings Allocation to about 6 months of anthracycline-based polychemotherapy (eg, with FAC or FEC) reduces the annual breast cancer death rate by about 38% (SE 5) for women younger than 50 years of age when diagnosed and by about 20% (SE 4) for those of age 50-69 years when diagnosed, largely irrespective of the use of tamoxifen and of oestrogen receptor (ER) status, nodal status, or other tumour characteristics. Such regimens are significantly (2p=0 . 0001 for recurrence, 2p<0 . 00001 for breast cancer mortality) more effective than CMF chemotherapy. Few women of age 70 years or older entered these chemotherapy trials. For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3), largely irrespective of the use of chemotherapy and of age (<50, 50-69, &GE; 70 years), progesterone receptor status, or other tumour characteristics. 5 years is significantly (2p<0 . 00001 for recurrence, 2p=0 . 01 for breast cancer mortality) more effective than just 1-2 years of tamoxifen. For ER-positive tumours, the annual breast cancer mortality rates are similar during years 0-4 and 5-14, as are the proportional reductions in them by 5 years of tamoxifen, so the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis. These results combine six meta-analyses: anthracycline-based versus no chemotherapy (8000 women); CMF-based versus no chemotherapy (14 000); anthracycline-based versus CMF-based chemotherapy (14 000); about 5 years of tamoxifen versus none (15 000); about 1-2 years of tamoxifen versus none (33 000); and about 5 years versus 1-2 years of tamoxifen (18 000). Finally, allocation to ovarian ablation or suppression (8000 women) also significantly reduces breast cancer mortality, but appears to do so only in the absence of other systemic treatments. For middle-aged women with ER-positive disease (the commonest type of breast cancer), the breast cancer mortality rate throughout the next 15 years would be approximately halved by 6 months of anthracycline-based chemotherapy (with a combination such as FAC or FEC) followed by 5 years of adjuvant tamoxifen. For, if mortality reductions of 38% (age <50 years) and 20% (age 50-69 years) from such chemotherapy were followed by a further reduction of 31% from tamoxifen in the risks that remain, the final mortality reductions would be 57% and 45%, respectively (and, the trial results could well have been somewhat stronger if there had been full compliance with the allocated treatments). Overall survival would be comparably improved, since these treatments have relatively small effects on mortality from the aggregate of all other causes. Interpretation Some of the widely practicable adjuvant drug treatments that were being tested in the 1980s, which substantially reduced 5-year recurrence rates (but had somewhat less effect on 5-year mortality rates), also substantially reduce 15-year mortality rates. Further improvements in long-term survival could well be available from newer drugs, or better use of older drugs.
  •  
5.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  • Palmer, Nicholette D, et al. (creator_code:aut_t)
  • A genome-wide association search for type 2 diabetes genes in African Americans.
  • 2012
  • record:In_t: PloS one. - San Francisco : Public Library of Science (PLoS). - 1932-6203. ; 7:1, s. e29202-
  • swepub:Mat_article_t (swepub:level_refereed_t)abstract
    • African Americans are disproportionately affected by type 2 diabetes (T2DM) yet few studies have examined T2DM using genome-wide association approaches in this ethnicity. The aim of this study was to identify genes associated with T2DM in the African American population. We performed a Genome Wide Association Study (GWAS) using the Affymetrix 6.0 array in 965 African-American cases with T2DM and end-stage renal disease (T2DM-ESRD) and 1029 population-based controls. The most significant SNPs (n = 550 independent loci) were genotyped in a replication cohort and 122 SNPs (n = 98 independent loci) were further tested through genotyping three additional validation cohorts followed by meta-analysis in all five cohorts totaling 3,132 cases and 3,317 controls. Twelve SNPs had evidence of association in the GWAS (P<0.0071), were directionally consistent in the Replication cohort and were associated with T2DM in subjects without nephropathy (P<0.05). Meta-analysis in all cases and controls revealed a single SNP reaching genome-wide significance (P<2.5×10(-8)). SNP rs7560163 (P = 7.0×10(-9), OR (95% CI) = 0.75 (0.67-0.84)) is located intergenically between RND3 and RBM43. Four additional loci (rs7542900, rs4659485, rs2722769 and rs7107217) were associated with T2DM (P<0.05) and reached more nominal levels of significance (P<2.5×10(-5)) in the overall analysis and may represent novel loci that contribute to T2DM. We have identified novel T2DM-susceptibility variants in the African-American population. Notably, T2DM risk was associated with the major allele and implies an interesting genetic architecture in this population. These results suggest that multiple loci underlie T2DM susceptibility in the African-American population and that these loci are distinct from those identified in other ethnic populations.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • navigation:Result_t 1-10 navigation:of_t 636
swepub:Mat_t
swepub:mat_article_t (483)
swepub:mat_conferencepaper_t (108)
swepub:mat_chapter_t (11)
swepub:mat_researchreview_t (8)
swepub:mat_publicationother_t (7)
swepub:mat_doctoralthesis_t (6)
deldatabas:search_more_t
swepub:mat_report_t (5)
swepub:mat_patent_t (5)
swepub:mat_review_t (2)
swepub:mat_book_t (1)
deldatabas:search_less_t
swepub:Level_t
swepub:level_refereed_t (502)
swepub:level_scientificother_t (123)
swepub:level_popularscientific_t (11)
swepub:Hitlist_author_t
Bengtsson, M (81)
Bengtsson, C (50)
Alfredsson, L (21)
KLARESKOG, L (20)
Bengtsson, J (20)
Johannsson, Gudmundu ... (19)
deldatabas:search_more_t
Bengtsson, L (17)
Bengtsson, S (16)
Bengtsson-Palme, Joh ... (15)
Bengtsson, NO (15)
Bengtsson, A. (14)
Bengtsson, Lars (13)
Bergh, J (13)
Bengtsson, Tore (13)
Heijl, Anders (13)
Bengtsson, Calle, 19 ... (13)
Bengtsson, E (13)
Nilsson, J. (12)
Saevarsdottir, S (12)
Bengtsson, Bengt-Åke ... (12)
Collins, R (11)
Jönsen, Andreas (11)
Rönnblom, Lars (11)
Rantapää-Dahlqvist, ... (11)
Witzgall, P. (11)
Bengtsson, P (11)
Gnant, M. (10)
Bengtsson, Anders (10)
Hatschek, T (10)
Gunnarsson, Iva (10)
Lissner, Lauren, 195 ... (10)
Bengtsson, Boel (10)
Bengtsson, Mats (10)
Soderberg, M (9)
Peto, R (9)
Blomqvist, C (9)
Jörntell, Henrik (9)
Bengtsson, B A (9)
Leske, M Cristina (9)
Persson, Kenneth M (8)
Lu, X. (8)
Malmstrom, P (8)
Svenungsson, Elisabe ... (8)
Bengtsson, Jörgen, 1 ... (8)
Gunnarsson, I (8)
Bengtsson, Anders A. (8)
Boström, Kristina Be ... (8)
Bengtsson, Fredrik (8)
Askling, J (8)
Bengtsson, B (8)
deldatabas:search_less_t
swepub:Hitlist_uni_t
swepub_uni:ki_t (174)
swepub_uni:lu_t (150)
swepub_uni:gu_t (103)
swepub_uni:uu_t (103)
swepub_uni:cth_t (36)
swepub_uni:su_t (33)
deldatabas:search_more_t
swepub_uni:umu_t (31)
swepub_uni:kth_t (28)
swepub_uni:liu_t (26)
swepub_uni:lnu_t (18)
swepub_uni:ri_t (12)
swepub_uni:slu_t (12)
swepub_uni:oru_t (10)
swepub_uni:kau_t (9)
swepub_uni:ltu_t (7)
swepub_uni:mau_t (7)
swepub_uni:hj_t (5)
swepub_uni:hh_t (3)
swepub_uni:hv_t (3)
swepub_uni:miun_t (3)
swepub_uni:mdh_t (2)
swepub_uni:hkr_t (1)
swepub_uni:hig_t (1)
swepub_uni:sh_t (1)
swepub_uni:hb_t (1)
swepub_uni:du_t (1)
deldatabas:search_less_t
hitlist:Language_t
language:Eng_t (625)
language:Swe_t (9)
language:Und_t (2)
hitlist:HSV_t
hsv:Cat_3_t (203)
hsv:Cat_1_t (119)
hsv:Cat_2_t (64)
hsv:Cat_5_t (22)
hsv:Cat_4_t (13)

hitlist:Year_t

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt tools:Close_t

tools:Permalink_label_t